These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 5003621

  • 1. Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.
    Keyes JW, Selawry OS, Hansen HH.
    Cancer Chemother Rep; 1971 Dec; 55(5):583-9. PubMed ID: 5003621
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of combination therapy with bleomycin (NSC-125066) and dibromodulcitol (NSC-104800) on squamous cell carcinoma in man.
    Onuma T, Holland JF, Sako K, Shedd DP.
    Cancer Chemother Rep; 1972 Oct; 56(5):625-33. PubMed ID: 4119907
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Clinical experiences with Dibromdulcitol (DBD) in the treatment of cancer].
    Nyiredy G, Gévai E.
    Bronches; 1971 Oct; 21(2):202-6. PubMed ID: 5126170
    [No Abstract] [Full Text] [Related]

  • 9. Dibromomannitol (NSC-94100): a clinical study of previously treated patients with refractory chronic myelocytic leukemia and blastic transformation.
    Levin WC, Mims CH, Haut A.
    Cancer Chemother Rep; 1974 Oct; 58(2):223-8. PubMed ID: 4598242
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and pharmacologic experience with dibromodulcitol (NSC-104800). A new antitumor agent.
    Sellei C, Eckhardt S, Horváth IP, Kralovánszky J, Institóris L.
    Cancer Chemother Rep; 1969 Dec; 53(6):377-84. PubMed ID: 4915082
    [No Abstract] [Full Text] [Related]

  • 12. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
    Vogel CL, Winton EF, Moore MR, Sohner S.
    Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
    Eagan RT, Frytak S, Nichols WC, Ingle JN, Creagan ET, Kvols LK.
    Cancer Treat Rep; 1981 Jul; 65(5-6):517-9. PubMed ID: 7195306
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical pharmacology of dibromohexitols.
    Eckhardt S.
    Haematologica; 1972 Apr; 57(11):722-31. PubMed ID: 4200307
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cytosine arabinoside (NSC-63878)--clinical brochure.
    Livingston RB, Carter SK.
    Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
    [No Abstract] [Full Text] [Related]

  • 18. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
    Luce JK, Thurman WG, Isaacs BL, Talley RW.
    Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
    [No Abstract] [Full Text] [Related]

  • 19. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL, Ryzin JV, Weiss AJ, Frelick RW, Moss SE.
    Oncology; 1975 Apr; 31(5-6):293-309. PubMed ID: 174041
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.